世界の乳がん用PARP阻害剤市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)

GlobalInfoResearchが発行した調査報告書(GIR21JY00001)
◆英語タイトル:Global PARP Inhibitors for Breast Cancer Market 2021 by Company, Regions, Type and Application, Forecast to 2026
◆商品コード:GIR21JY00001
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2021年7月(※2024年版があります。お問い合わせください。)
◆ページ数:109
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2~3日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

GlobalInfoResearch社の本調査レポートでは、乳がん用PARP阻害剤の世界市場を広く調査・分析し、今後の市場展望をまとめております。乳がん用PARP阻害剤の種類別市場規模(オラパリブ、タラゾパリブ)、用途別市場規模(病院、クリニック、ドラッグセンター、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・メーカー情報(企業概要、製品概要、販売量、価格、売上):AstraZeneca、Everest Pharmaceuticals、Pfizer
・メーカー別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:オラパリブ、タラゾパリブ
・用途別分析2016年-2026年:病院、クリニック、ドラッグセンター、その他
・乳がん用PARP阻害剤の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・乳がん用PARP阻害剤のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・乳がん用PARP阻害剤のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・乳がん用PARP阻害剤の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・乳がん用PARP阻害剤の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
【レポートの概要】

The PARP Inhibitors for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global PARP Inhibitors for Breast Cancer size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global PARP Inhibitors for Breast Cancer market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
PARP Inhibitors for Breast Cancer market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Olaparib
Talazoparib

Market segment by Application, can be divided into
Hospital
Clinic
Drug Center
Other

Market segment by players, this report covers
AstraZeneca
Everest Pharmaceuticals
Pfizer

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

【レポートの目次】

1 Market Overview
1.1 Product Overview and Scope of PARP Inhibitors for Breast Cancer
1.2 Classification of PARP Inhibitors for Breast Cancer by Type
1.2.1 Overview: Global PARP Inhibitors for Breast Cancer Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global PARP Inhibitors for Breast Cancer Revenue Market Share by Type in 2020
1.2.3 Olaparib
1.2.4 Talazoparib
1.3 Global PARP Inhibitors for Breast Cancer Market by Application
1.3.1 Overview: Global PARP Inhibitors for Breast Cancer Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global PARP Inhibitors for Breast Cancer Market Size & Forecast
1.5 Global PARP Inhibitors for Breast Cancer Market Size and Forecast by Region
1.5.1 Global PARP Inhibitors for Breast Cancer Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global PARP Inhibitors for Breast Cancer Market Size by Region, (2016-2021)
1.5.3 North America PARP Inhibitors for Breast Cancer Market Size and Prospect (2016-2026)
1.5.4 Europe PARP Inhibitors for Breast Cancer Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size and Prospect (2016-2026)
1.5.6 South America PARP Inhibitors for Breast Cancer Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa PARP Inhibitors for Breast Cancer Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 PARP Inhibitors for Breast Cancer Market Drivers
1.6.2 PARP Inhibitors for Breast Cancer Market Restraints
1.6.3 PARP Inhibitors for Breast Cancer Trends Analysis
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca PARP Inhibitors for Breast Cancer Product and Solutions
2.1.4 AstraZeneca PARP Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Everest Pharmaceuticals
2.2.1 Everest Pharmaceuticals Details
2.2.2 Everest Pharmaceuticals Major Business
2.2.3 Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Product and Solutions
2.2.4 Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Everest Pharmaceuticals Recent Developments and Future Plans
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer PARP Inhibitors for Breast Cancer Product and Solutions
2.3.4 Pfizer PARP Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Pfizer Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global PARP Inhibitors for Breast Cancer Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 PARP Inhibitors for Breast Cancer Players Market Share
3.2.2 Top 10 PARP Inhibitors for Breast Cancer Players Market Share
3.2.3 Market Competition Trend
3.3 PARP Inhibitors for Breast Cancer Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global PARP Inhibitors for Breast Cancer Revenue and Market Share by Type (2016-2021)
4.2 Global PARP Inhibitors for Breast Cancer Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global PARP Inhibitors for Breast Cancer Revenue Market Share by Application (2016-2021)
5.2 PARP Inhibitors for Breast Cancer Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America PARP Inhibitors for Breast Cancer Revenue by Type (2016-2026)
6.2 North America PARP Inhibitors for Breast Cancer Revenue by Application (2016-2026)
6.3 North America PARP Inhibitors for Breast Cancer Market Size by Country
6.3.1 North America PARP Inhibitors for Breast Cancer Revenue by Country (2016-2026)
6.3.2 United States PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
6.3.3 Canada PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
6.3.4 Mexico PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe PARP Inhibitors for Breast Cancer Revenue by Type (2016-2026)
7.2 Europe PARP Inhibitors for Breast Cancer Revenue by Application (2016-2026)
7.3 Europe PARP Inhibitors for Breast Cancer Market Size by Country
7.3.1 Europe PARP Inhibitors for Breast Cancer Revenue by Country (2016-2026)
7.3.2 Germany PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
7.3.3 France PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
7.3.4 United Kingdom PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
7.3.5 Russia PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
7.3.6 Italy PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific PARP Inhibitors for Breast Cancer Revenue by Type (2016-2026)
8.2 Asia-Pacific PARP Inhibitors for Breast Cancer Revenue by Application (2016-2026)
8.3 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Region
8.3.1 Asia-Pacific PARP Inhibitors for Breast Cancer Revenue by Region (2016-2026)
8.3.2 China PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
8.3.3 Japan PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
8.3.4 South Korea PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
8.3.5 India PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
8.3.7 Australia PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America PARP Inhibitors for Breast Cancer Revenue by Type (2016-2026)
9.2 South America PARP Inhibitors for Breast Cancer Revenue by Application (2016-2026)
9.3 South America PARP Inhibitors for Breast Cancer Market Size by Country
9.3.1 South America PARP Inhibitors for Breast Cancer Revenue by Country (2016-2026)
9.3.2 Brazil PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
9.3.3 Argentina PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa PARP Inhibitors for Breast Cancer Revenue by Type (2016-2026)
10.2 Middle East & Africa PARP Inhibitors for Breast Cancer Revenue by Application (2016-2026)
10.3 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Country
10.3.1 Middle East & Africa PARP Inhibitors for Breast Cancer Revenue by Country (2016-2026)
10.3.2 Turkey PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
10.3.4 UAE PARP Inhibitors for Breast Cancer Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

...

【掲載企業】

AstraZeneca、Everest Pharmaceuticals、Pfizer

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の乳がん用PARP阻害剤市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)(Global PARP Inhibitors for Breast Cancer Market 2021 by Company, Regions, Type and Application, Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。